Clinical Trials Logo

Watchman LAA Closure Device clinical trials

View clinical trials related to Watchman LAA Closure Device.

Filter by:
  • None
  • Page 1

NCT ID: NCT03539055 Completed - Atrial Fibrillation Clinical Trials

Efficacy of Short Term Dabigatran Etexilate Followed by Aspirin Monotherapy After LAA (Left Atrial Appendage) Device Closure (the DEA-LAA Study).

DEA-LAA
Start date: September 1, 2018
Phase: Phase 4
Study type: Interventional

Single arm, prospective unblinded study on post Watchman LAA closure device implant anti-coagulation management at a primary center (Vanderbilt Medical Center) and up to 5 additional high volume LAA implant centers. This trial will be designed to evaluate the use of dabigatran for 90 days post implantation of an LAA closure device (Watchman LAA Closure Device, Boston Scientific Inc.) to prevent device related thrombus.